miR-107 inhibition upregulates CAB39 and activates AMPK-Nrf2 signaling to protect osteoblasts from dexamethasone-induced oxidative injury and cytotoxicity.

AMP-Activated Protein Kinases / genetics Antagomirs / pharmacology Apoptosis / drug effects Calcium-Binding Proteins / genetics Cell Line Dexamethasone / adverse effects Gene Knockout Techniques Humans MicroRNAs / antagonists & inhibitors NF-E2-Related Factor 2 / genetics Osteoblasts Osteoporosis / chemically induced Oxidative Stress / drug effects RNA, Small Interfering / metabolism Reactive Oxygen Species / metabolism Signal Transduction / drug effects Up-Regulation / drug effects
AMPK-Nrf2 signaling CAB39 dexamethasone miR-107 osteoblasts

Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
11 06 2020
Historique:
received: 27 12 2019
accepted: 18 05 2020
pubmed: 13 6 2020
medline: 9 3 2021
entrez: 13 6 2020
Statut: ppublish

Résumé

To human osteoblasts dexamethasone (DEX) treatment induces significant oxidative injury and cytotoxicity. Inhibition of CAB39 (calcium binding protein 39)-targeting microRNA can induce CAB39 upregulation, activating AMP-activated protein kinase (AMPK) signaling and offering osteoblast cytoprotection. Here we identified a novel CAB39-targeting miRNA: the microRNA-107 (miR-107). RNA-Pull down assay results demonstrated that the biotinylated-miR-107 directly binds to

Identifiants

DOI: 10.18632/aging.103341 PMID: 32527986 PMC: PMC7343481
pubmed: 32527986
pii: 103341
doi: 10.18632/aging.103341
pmc: PMC7343481
doi:

Substances chimiques

Antagomirs 0
CAB39 protein, human 0
Calcium-Binding Proteins 0
MIRN107 microRNA, human 0
MicroRNAs 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
RNA, Small Interfering 0
Reactive Oxygen Species 0
Dexamethasone 7S5I7G3JQL
AMP-Activated Protein Kinases EC 2.7.11.31
PRKAA1 protein, human EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11754-11767

Références

Cell Signal. 2014 Jan;26(1):1-8
pubmed: 24080159
Oncotarget. 2016 Oct 25;7(43):70613-70622
pubmed: 27661114
Cell Commun Signal. 2018 Nov 15;16(1):81
pubmed: 30442144
Oncotarget. 2017 Dec 15;9(2):2017-2027
pubmed: 29416749
Biochem Biophys Res Commun. 2019 Jan 15;508(3):921-927
pubmed: 30545629
Nat Cell Biol. 2011 Sep 02;13(9):1016-23
pubmed: 21892142
J Agric Food Chem. 2019 Jan 9;67(1):120-131
pubmed: 30525573
Nutrients. 2017 Dec 02;9(12):
pubmed: 29207476
Oncotarget. 2017 Jan 10;8(2):2594-2603
pubmed: 27911877
Cell Death Dis. 2019 Nov 14;10(11):866
pubmed: 31727877
Free Radic Biol Med. 2019 Nov 1;143:387-396
pubmed: 31446056
Biochem Biophys Res Commun. 2015 May 1;460(2):157-63
pubmed: 25753204
Biochem Biophys Res Commun. 2016 Dec 9;481(3-4):212-218
pubmed: 27884298
Cell. 2006 Sep 8;126(5):955-68
pubmed: 16959574
Mol Cell. 2010 Mar 12;37(5):620-32
pubmed: 20227367
Biochem Biophys Res Commun. 2017 Jun 03;487(3):660-665
pubmed: 28438603
Mol Cell Biochem. 2019 Oct;460(1-2):113-121
pubmed: 31313024
Cell Physiol Biochem. 2018;51(4):1908-1920
pubmed: 30504702
Free Radic Biol Med. 2015 Nov;88(Pt B):417-426
pubmed: 25843659
Front Oncol. 2013 Jul 15;3:175
pubmed: 23875169
Biochem Biophys Res Commun. 2019 Jun 30;514(3):777-784
pubmed: 31079921
Nature. 2018 Apr 5;556(7699):113-117
pubmed: 29590092
Clin Sci (Lond). 2012 Jun;122(12):555-73
pubmed: 22390198
Oncotarget. 2017 Aug 24;8(62):104867-104876
pubmed: 29285219
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Cell Physiol Biochem. 2018;51(1):31-45
pubmed: 30439702
Biochem Biophys Res Commun. 2016 Mar 18;471(4):545-52
pubmed: 26891866
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6
pubmed: 11904383
J Bone Miner Metab. 2009;27(2):140-8
pubmed: 19066717
Redox Biol. 2017 Aug;12:311-324
pubmed: 28285192
Oncogene. 2018 May;37(21):2890-2902
pubmed: 29520106
Food Chem Toxicol. 2012 Mar;50(3-4):583-9
pubmed: 22198064
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1014-1021
pubmed: 29175330
Curr Rheumatol Rep. 2011 Jun;13(3):233-40
pubmed: 21365209
Biochem Biophys Res Commun. 2016 Jan 8;469(2):281-7
pubmed: 26631960
Biochem Biophys Res Commun. 2016 Jan 15;469(3):753-60
pubmed: 26686418
Biochemistry (Mosc). 2016 Apr;81(4):315-28
pubmed: 27293089
Mol Vis. 2013 Jun 27;19:1406-12
pubmed: 23825920
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
Front Pediatr. 2015 Aug 24;3:69
pubmed: 26380245
Biochem Biophys Res Commun. 2019 Aug 27;516(3):645-652
pubmed: 31242973
Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6
pubmed: 23743198
Biochem J. 2012 Jul 1;445(1):11-27
pubmed: 22702974
Biochem Biophys Res Commun. 2018 Jul 7;502(1):62-68
pubmed: 29778534
Oncotarget. 2017 Feb 7;8(6):10543-10552
pubmed: 28060740
Biochem Biophys Res Commun. 2018 Feb 26;497(1):339-346
pubmed: 29432731
Mol Cell Biol. 2016 Jun 29;36(14):1931-42
pubmed: 27161318
Biochem Biophys Res Commun. 2016 Oct 7;479(1):54-60
pubmed: 27614310
Biochem Biophys Res Commun. 2015 Mar 13;458(3):568-575
pubmed: 25680461
PLoS One. 2017 Apr 26;12(4):e0175507
pubmed: 28445531
Curr Biol. 2000 Apr 20;10(8):439-48
pubmed: 10801415
Cell Signal. 2014 Jan;26(1):102-9
pubmed: 23899558
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Yu Zhuang (Y)

Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.

Shouguo Wang (S)

Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.

Haodong Fei (H)

Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.

Feng Ji (F)

Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.

Peng Sun (P)

Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › AMP-Activated Protein Kinases › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Polynucléotides › Oligonucléotides › Antagomirs › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de transport › Protéines de liaison au calcium › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Stéroïdes fluorés › Dexaméthasone › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › Techniques de knock-out de gènes › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteur-2 apparenté à NF-E2 › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Ostéoblastes › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Maladies osseuses métaboliques › Ostéoporose › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › Petit ARN interférent › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Espèces réactives de l'oxygène › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › miR-107 inhibition upregulates CAB39 and...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › miR-107 inhibition upregulates CAB39 and...